{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:42:15Z","timestamp":1790347335784,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Despite frequent vancomycin prescribing, achieving optimal therapeutic outcomes is challenging due to its complex pharmacokinetic (PK) and pharmacodynamic (PD) properties. Those characteristics are influenced by various parameters, including both genetic and non-genetic variables, rendering accurate dosing and monitoring challenging for clinicians. This systematic review was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, ensuring a standardized and comprehensive approach to the literature search, data extraction, and reporting. We searched the publications for all appropriate evidence on genetic and non-genetic factors affecting vancomycin population PKs and PDs from 2014 to January 2024. This review\u2019s initial electronic database search found 1,543 relevant studies. Following the removal of automation-ineligible records and in-depth title relevance screening, the titles and abstracts of 67 publications were examined. After duplicate removal, 50 articles remained, and 23 were ultimately included based on the predefined inclusion and exclusion criteria. Vancomycin exhibits substantial PK and PD variability, and standard dosing often fails to achieve therapeutic targets. Area Under the Curve -guided therapeutic drug monitoring remains the most reliable strategy, while genetic factors appear to play a limited, toxicity-focused role.<\/jats:p>","DOI":"10.4103\/ijp.ijp_878_25","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:02:48Z","timestamp":1777575768000},"page":"176-188","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Genetic and nongenetic factors affecting vancomycin population pharmacokinetics and pharmacodynamics: A systematic review"],"prefix":"10.4103","volume":"58","author":[{"given":"Dimas Adhi","family":"Pradana","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Indonesia, Yogyakarta, Indoneisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlina","family":"Marfianti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Universitas Islam Indonesia, Yogyakarta, Indoneisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Wibowo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Indonesia, Yogyakarta, Indoneisa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"R1-20260501","doi-asserted-by":"crossref","first-page":"e0005922","DOI":"10.1128\/cmr.00059-22","article-title":"Therapeutics for vancomycin-resistant enterococcal bloodstream infections","volume":"36","author":"Cairns","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"R2-20260501","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/br.2021.1490","article-title":"Mechanisms of gram-positive vancomycin resistance (review)","volume":"16","author":"Selim","year":"2022","journal-title":"Biomed Rep"},{"key":"R3-20260501","first-page":"e31486","article-title":"An update on treatment options for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: A systematic review","volume":"14","author":"Mahjabeen","year":"2022","journal-title":"Cureus"},{"key":"R4-20260501","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3390\/ijms23042052","article-title":"Vancomycin-associated acute kidney injury: A narrative review from pathophysiology to clinical application","volume":"23","author":"Kan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R5-20260501","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/antibiotics12040697","article-title":"Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: A systematic review and meta-analysis","volume":"12","author":"Kawasuji","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R6-20260501","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R7-20260501","doi-asserted-by":"crossref","first-page":"e0127791","DOI":"10.1371\/journal.pone.0127791","article-title":"Genome-wide association study of serum creatinine levels during vancomycin therapy","volume":"10","author":"Van","year":"2015","journal-title":"PLoS One"},{"key":"R8-20260501","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/DDDT.S432439","article-title":"Population pharmacokinetics and model-based dose optimization of vancomycin in Sudanese adult patients with renal impairment","volume":"18","author":"Ahmed","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R9-20260501","first-page":"17","article-title":"Vancomycin therapeutic drug monitoring","volume":"5","author":"Shenoy","year":"2023","journal-title":"Pediatr Infect Dis"},{"key":"R10-20260501","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jpids\/piaa078","article-title":"A moving target-vancomycin therapeutic monitoring","volume":"9","author":"Burns","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R11-20260501","doi-asserted-by":"crossref","first-page":"e22376","DOI":"10.1097\/MD.0000000000022376","article-title":"Adverse reactions of vancomycin in humans: A protocol for meta-analysis","volume":"99","author":"Peng","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R12-20260501","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1515\/med-2018-0068","article-title":"Pharmacokinetics of vancomycin in patients with different renal function levels","volume":"13","author":"Zaric","year":"2018","journal-title":"Open Med (Wars)"},{"key":"R13-20260501","doi-asserted-by":"crossref","first-page":"954596","DOI":"10.3389\/fphar.2022.954596","article-title":"Associations of HLA-a and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R14-20260501","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"R15-20260501","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3747\/pdi.2013.00156","article-title":"The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis","volume":"35","author":"Stevenson","year":"2015","journal-title":"Perit Dial Int"},{"key":"R16-20260501","doi-asserted-by":"crossref","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R17-20260501","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FTD.0000000000000153","article-title":"Validation of a pediatric population pharmacokinetic model for vancomycin","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R18-20260501","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jiph.2015.01.011","article-title":"Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application","volume":"8","author":"Tafelski","year":"2015","journal-title":"J Infect Public Health"},{"key":"R19-20260501","doi-asserted-by":"crossref","first-page":"e0141016","DOI":"10.1371\/journal.pone.0141016","article-title":"Trough concentrations of vancomycin in patients undergoing extracorporeal membrane oxygenation","volume":"10","author":"Park","year":"2015","journal-title":"PLoS One"},{"key":"R20-20260501","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bjid.2016.06.008","article-title":"Serum levels of vancomycin: Is there a prediction using doses in mg\/kg\/day or m (2)\/day for neonates?","volume":"20","author":"Romanelli","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"R21-20260501","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/psp4.12112","article-title":"A population pharmacokinetic model for vancomycin in adult patients receiving extracorporeal membrane oxygenation therapy","volume":"5","author":"Moore","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R22-20260501","doi-asserted-by":"crossref","first-page":"874401","DOI":"10.3389\/fcimb.2022.874401","article-title":"Pharmacokinetic\/pharmacodynamic target attainment of vancomycin, at three reported infusion modes, for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections in critically ill patients: Focus on novel infusion mode","volume":"12","author":"Song","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R23-20260501","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5935\/0103-507X.20160071","article-title":"Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients","volume":"28","author":"Obara","year":"2016","journal-title":"Rev Bras Ter Intensiva"},{"key":"R24-20260501","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/aas.12897","article-title":"Vancomycin levels are frequently subtherapeutic in critically ill patients: A prospective observational study","volume":"61","author":"Bakke","year":"2017","journal-title":"Acta Anaesthesiol Scand"},{"issue":"11","key":"R25-20260501","first-page":"1537","article-title":"The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material","volume":"99-B","author":"Wahl","year":"2017","journal-title":"Bone &Joint Journal"},{"key":"R26-20260501","doi-asserted-by":"crossref","first-page":"eAO4396","DOI":"10.31744\/einstein_journal\/2019AO4396","article-title":"Effective vancomycin concentrations in children: A cross-sectional study","volume":"17","author":"Alves","year":"2019","journal-title":"Einstein (Sao Paulo)"},{"key":"R27-20260501","doi-asserted-by":"crossref","first-page":"e0216801","DOI":"10.1371\/journal.pone.0216801","article-title":"Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration","volume":"14","author":"Westra","year":"2019","journal-title":"PLoS One"},{"key":"R28-20260501","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3855\/jidc.9800","article-title":"Prospective evaluation of vancomycin therapeutic usage and trough levels monitoring","volume":"12","author":"Kabbara","year":"2018","journal-title":"J Infect Dev Ctries"},{"key":"R29-20260501","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s40262-020-00902-1","article-title":"Pharmacokinetic assessment of pre- and post-oxygenator vancomycin concentrations in extracorporeal membrane oxygenation: A prospective observational study","volume":"59","author":"Mahmoud","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R30-20260501","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/FTD.0000000000000796","article-title":"Effect of cystatin C on vancomycin clearance estimation in critically ill children using a population pharmacokinetic modeling approach","volume":"42","author":"Downes","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R31-20260501","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41598-021-82312-2","article-title":"Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units","volume":"11","author":"Lin","year":"2021","journal-title":"Sci Rep"},{"key":"R32-20260501","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/DDDT.S285488","article-title":"Individualized vancomycin dosing with therapeutic drug monitoring and pharmacokinetic consultation service: A large-scale retrospective observational study","volume":"15","author":"Kim","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R33-20260501","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bcpt.13646","article-title":"Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data","volume":"129","author":"Hirai","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R34-20260501","doi-asserted-by":"crossref","first-page":"e0373923","DOI":"10.1128\/spectrum.03739-23","article-title":"Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: A multicenter retrospective study","volume":"12","author":"Ishigo","year":"2024","journal-title":"Microbiol Spectr"},{"key":"R35-20260501","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0002-9440(10)64438-0","article-title":"Up-regulation of connexin43 in glomerular podocytes in response to injury","volume":"161","author":"Yaoita","year":"2002","journal-title":"Am J Pathol"},{"key":"R36-20260501","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1152\/ajprenal.00255.2010","article-title":"Alteration of connexin expression is an early signal for chronic kidney disease","volume":"301","author":"Toubas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"R37-20260501","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/j.1476-5381.2010.00860.x","article-title":"Disruption of gap junctions attenuates aminoglycoside-elicited renal tubular cell injury","volume":"160","author":"Yao","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R38-20260501","doi-asserted-by":"crossref","first-page":"563967","DOI":"10.3389\/fphar.2020.563967","article-title":"Population pharmacokinetics of vancomycin in kidney transplant recipients: Model building and parameter optimization","volume":"11","author":"Ma","year":"2020","journal-title":"Front Pharmacol"},{"key":"R39-20260501","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/jcpt.12995","article-title":"A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKD-EPI estimation","volume":"44","author":"Kim","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"R40-20260501","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3109\/0886022X.2014.917560","article-title":"Diuretics associated acute kidney injury: Clinical and pathological analysis","volume":"36","author":"Wu","year":"2014","journal-title":"Ren Fail"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_878_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:57Z","timestamp":1786649937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_878_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_878_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}